This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Span, P. N. Articles by Sweep, F. C.G.J. Search for Related Content PubMed PubMed Citation Articles by Span, P. N. Articles by Sweep, F. C.G.J. Social Bookmarking                            What's this?

Mammaglobin Is Associated With Low-Grade, Steroid Receptor-Positive Breast Tumors From Postmenopausal Patients, and Has Independent Prognostic Value for Relapse-Free Survival Time

From the Departments of Chemical Endocrinology and Medical Oncology, University Medical Center Nijmegen, Nijmegen; Division of Endocrine Oncology, Department of Medical Oncology, Erasmus Medical Center—Daniel den Hoed, Rotterdam, the Netherlands; and Division of Laboratory Medicine, Washington University School of Medicine, St Louis, MO

Address reprint requests to P.N. Span, PhD, 530 Department of Chemical Endocrinology, University Medical Center Nijmegen, PO Box 9101, 6500 HB Nijmegen, the Netherlands; e-mail: p.span{at}ace.umcn.nl

PURPOSE: The tumor mRNA expression levels of mammaglobin, a novel breast-specific and breast cancer-associated marker, were correlated with disease outcome in 280 patients with primary breast cancer.

PATIENTS AND METHODS: Mammaglobin expression levels were assessed by quantitative reverse transcriptase polymerase chain reaction in frozen tumor tissue from breast cancer patients with a median age of 60 years (range, 30 to 88 years) and a median follow-up of 85 months (range, 2 to 169 months).

RESULTS: High expression levels were associated with low-grade tumors (P = .018), with positive estrogen and progesterone receptor status (P < .001), and postmenopausal status (P = .010). In the analysis of all patients, low tumor mammaglobin expression levels predicted an early relapse both in Cox univariate (hazard ratio [HR], 0.52; 95% CI, 0.34 to 0.79; P = .002) and multivariate regression analyses corrected for the traditional prognostic factors (HR, 0.55; 95% CI, 0.35 to 0.88; P = .012). The association of mammaglobin expression with the rate of relapse was particularly favorable in patients who received adjuvant tamoxifen treatment (HR, 0.35; 95% CI, 0.17 to 0.71; P = .004).

CONCLUSION: These results demonstrate that the assessment of the tumor mRNA expression level of the breast-specific protein mammaglobin could be useful to stratify patients for individual adjuvant treatment strategies.

Presented in part at the 2002 European Society for Medical Oncology meeting, October 18–22, Nice, France.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. Schmidt, A. Victor, D. Bratzel, D. Boehm, C. Cotarelo, A. Lebrecht, W. Siggelkow, J. G. Hengstler, A. Elsasser, M. Gehrmann, et al. Long-term outcome prediction by clinicopathological risk classification algorithms in node-negative breast cancer--comparison between Adjuvant!, St Gallen, and a novel risk algorithm used in the prospective randomized Node-Negative-Breast Cancer-3 (NNBC-3) trial Ann. Onc., February 1, 2009; 20(2): 258 - 264. [Abstract] [Full Text] [PDF]

				M. Smid, Y. Wang, Y. Zhang, A. M. Sieuwerts, J. Yu, J. G.M. Klijn, J. A. Foekens, and J. W.M. Martens Subtypes of Breast Cancer Show Preferential Site of Relapse Cancer Res., May 1, 2008; 68(9): 3108 - 3114. [Abstract] [Full Text] [PDF]

				M. Ignatiadis, G. Kallergi, M. Ntoulia, M. Perraki, S. Apostolaki, M. Kafousi, G. Chlouverakis, E. Stathopoulos, E. Lianidou, V. Georgoulias, et al. Prognostic Value of the Molecular Detection of Circulating Tumor Cells Using a Multimarker Reverse Transcription-PCR Assay for Cytokeratin 19, Mammaglobin A, and HER2 in Early Breast Cancer Clin. Cancer Res., May 1, 2008; 14(9): 2593 - 2600. [Abstract] [Full Text] [PDF]

				A. Gutierrez-Fernandez, A. Fueyo, A. R. Folgueras, C. Garabaya, C. J. Pennington, S. Pilgrim, D. R. Edwards, D. L. Holliday, J. L. Jones, P. N. Span, et al. Matrix Metalloproteinase-8 Functions as a Metastasis Suppressor through Modulation of Tumor Cell Adhesion and Invasion Cancer Res., April 15, 2008; 68(8): 2755 - 2763. [Abstract] [Full Text] [PDF]

				M. Lacroix Significance, detection and markers of disseminated breast cancer cells Endocr. Relat. Cancer, December 1, 2006; 13(4): 1033 - 1067. [Abstract] [Full Text] [PDF]

				P. N. Span, F. C.G.J. Sweep, K. Mikhitarian, W. E. Gillanders, D. J. Cole, M. Mitas, and M. Reinholz Mammaglobin as Molecular Marker of Breast Cancer (Micro)Metastases Clin. Cancer Res., October 1, 2005; 11(19): 7043 - 7044. [Full Text] [PDF]

				J. L. Bernstein, J. H. Godbold, G. Raptis, M. A. Watson, B. Levinson, S. A. Aaronson, and T. P. Fleming Identification of Mammaglobin as a Novel Serum Marker for Breast Cancer Clin. Cancer Res., September 15, 2005; 11(18): 6528 - 6535. [Abstract] [Full Text] [PDF]

				M. M. Reinholz, A. Nibbe, L. M. Jonart, K. Kitzmann, V. J. Suman, J. N. Ingle, R. Houghton, B. Zehentner, P. C. Roche, and W. L. Lingle Evaluation of a Panel of Tumor Markers for Molecular Detection of Circulating Cancer Cells in Women with Suspected Breast Cancer Clin. Cancer Res., May 15, 2005; 11(10): 3722 - 3732. [Abstract] [Full Text] [PDF]

				O. Zach and D. Lutz Mammaglobin Remains a Useful Marker for the Detection of Breast Cancer Cells in Peripheral Blood J. Clin. Oncol., May 1, 2005; 23(13): 3160 - 3160. [Full Text] [PDF]

				P.N. Span, C.G.J. Sweep, L.V.A.M. Beex, and J.A. Foekens In Reply: J. Clin. Oncol., May 1, 2005; 23(13): 3160 - 3161. [Full Text] [PDF]

				P. N. Span, N. I. Grebenchtchikov, A. Geurts-Moespot, and F. C.G.J. Sweep Concerns about Mammaglobin Assays Clin. Chem., February 1, 2005; 51(2): 474 - 475. [Full Text] [PDF]